MTMariana Costa Taveira

Mariana Costa Taveira

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mariana Costa Taveira has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Subjective cognitive symptoms improve following effective migraine treatment: A patient‐reported outcome study

    by Mariana Costa Taveira, Filipa Dourado Sotero, João Nobre, Mariana Dias da Costa, Rita Rato, Andreia Costa, Bárbara Martins, Maria Roque, Isabel Pavão Martins

    Objectives/Background: Our objective was to investigate whether subjective cognitive symptoms improve after effective preventive migraine treatment. Subjective cognitive symptoms, such as memory and concentration difficulties, are increasingly recognized as part of the clinical spectrum of migraine. We aimed to evaluate whether subjective cognitive symptoms improve with effective preventive migraine treatment acting predominantly outside the central nervous system. Methods: We conducted a prospective two‐center observational cohort study with a pre–post (within‐person) design including adults with migraine diagnosed according to the International Classification of Headache Disorders, 3rd edition criteria, who initiated preventive treatment with either anti‐calcitonin gene‐related peptide/calcitonin gene‐related peptide receptor monoclonal antibodies or onabotulinumtoxinA at two tertiary headache centers in Portugal between October 2023 and August 2025. Treatment response was defined as a ≥50% reduction in monthly moderate to severe headache days in patients with episodic migraine and a ≥30% reduction in those with chronic migraine, assessed between baseline and 3–6 months of follow‐up. Subjective cognitive symptoms, assessed using the Subjective Memory Complaints scale, and depression and anxiety symptoms, evaluated with the Hospital Anxiety and Depression Scale, were compared between baseline and follow‐up according to treatment responder status. Results: Participants ( N = 96, mean age 42.4±12.0 years, 94/96 [98%] women, 68/96 [71%] with chronic migraine), received either anti‐calcitonin gene‐related peptide/receptor monoclonal antibodies ( n = 65) or onabotulinumtoxinA ( n = 31), and 51 responded to treatment. Treatment responders showed greater improvement in subjective cognitive symptoms than nonresponders ( B = −2.22, 95% CI = −3.62 to −0.82, p = 0.002), regardless of preventive treatment type ( B = 0.17, 95% CI = −1.34 to 1.68, p = 0.825) and baseline depression ( B = 0.02, 95% CI = −0.21 to 0.24, p = 0.894) and anxiety ( B = −0.06, 95% CI = −0.25 to 0.13, p = 0.545) symptoms. Although in patients with borderline or clinically significant depression symptoms, cognitive improvement was primarily associated with improvement in depression symptoms ( B = 0.35, 95% CI = 0.03–0.68, p = 0.033; B = 0.61, 95% CI = 0.32–0.90, p < 0.001; respectively), among patients without baseline depression symptoms, cognitive improvement was only associated with treatment response ( B = −1.77, 95% CI = −3.32 to −0.21, p = 0.027). Conclusion: This study shows that effective preventive treatment is associated with significant improvement in subjective cognitive symptoms, highlighting their responsiveness to treatment and relevance to patient‐reported outcomes. image

  • Validation of the DIAS 3 Score in Cerebral Venous Thrombosis Patients Treated by Decompressive Surgery

    by Mariana C. Taveira, Mayte Sanchez van Kammen, Sanjith Aaron, Jorge M. Ferreira, Jonathan M. Coutinho, Patrícia Canhão, Adriana B. Conforto, Antonio Arauz, Marta Carvalho, Jaime Masjuan, et al.

    Introduction: Cerebral venous thrombosis (CVT) is associated with a risk of late seizures, particularly in patients with severe disease requiring decompressive surgery. The DIAS3 score was developed to predict late seizures after CVT, but its performance in surgically treated patients is unknown. We aimed to validate the DIAS3 score in a high-risk cohort of CVT patients treated by decompressive surgery. Methods: This was a substudy of the DECOMPRESS2 – a prospective, multicenter cohort, including patients with CVT treated with decompressive surgery. Patients with available data on the occurrence and timing of seizures following CVT were included. Late seizures were defined as those occurring more than 7 days after CVT diagnosis, up to 1-year follow-up. We calculated DIAS3 score for all included patients. Predictive performance was assessed only for the 1-year risk of late seizures. Discrimination was evaluated using receiver operating characteristic analysis, and calibration by comparing predicted and observed seizure risks. Diagnostic performance was assessed across multiple probability thresholds. Results: In total, 89 patients were included (median age 38 years; 69.7% female). Late seizures occurred in 22 (24.7%) patients. The mean predicted 1-year seizure risk according to the DIAS3 score was 28.4%. The DIAS3 score showed poor discrimination (area under the curve 0.44, 95% confidence interval 0.30–0.59) and poor calibration. Across all tested thresholds, sensitivity and specificity showed an expected trade-off, but overall predictive accuracy was limited. Conclusion: The DIAS3 score demonstrated poor discrimination and calibration in CVT patients treated by decompressive surgery. These findings suggest that the DIAS3 score should not be used to predict late seizures in this high-risk surgical subgroup.

  • Open Access

    Timing of starting anticoagulation following decompressive surgery for cerebral vein and sinus thrombosis: An observational study

    by Mariana C Taveira, Sanjith Aaron, Jorge M Ferreira, Jonathan M Coutinho, Patrícia Canhão, Adriana Conforto, Antonio Arauz, Marta Carvalho, Jaime Masjuan, Vijay K Sharma, et al.

    Background: Anticoagulation is the mainstay acute therapy for cerebral venous thrombosis (CVT). Decompressive surgery is required in a small minority of patients with large parenchymal lesions and impending herniation, which requires a temporary suspension of anticoagulation. Aim: The objective of this study was to identify the optimal timing for starting or resuming anticoagulation following decompressive surgery. Methods: Data were collected from the Decompressive Surgery for CVT Study 2 (DECOMPRESS2), a prospective multinational cohort observational study of 118 patients with severe CVT treated by decompressive surgery. We assessed the frequency of new hemorrhagic and venous thrombotic events from admission to discharge in patients who started or resumed anticoagulation 2) at discharge and at 1 year follow-up and compared between the two groups. Results: Of the 90 patients available for analysis, 35 (39%) started or resumed anticoagulation within the first 24 h after surgery while 55 (61%) did so later than 24 h. Overall frequency of patients with new hemorrhagic or venous thrombotic events from admission to discharge was 26.7% (24 patients), without crude or adjusted for the propensity score statistically significant difference between the early and late anticoagulation groups (2 = 0.33, p = 0.57). The distribution of major hemorrhagic events was also comparable: 8 (23%) bleedings in the 2 = 0.24, p = 0.62). No CVT recurred. Two venous thrombotic events occurred in <24 h (6%) and 5 in the ⩾24 h (9%) group. There was no association between anticoagulation timing and death or dependence (mRS 3-6) at discharge (OR: 1.65. 95% CI: 0.30 to 9.01, p = 0.56), or at 1 year follow-up (OR: 2.19, 95% CI: 0.78 to 6.10, p = 0.14). Conclusions: The results of this cohort study suggest that the timing of anticoagulation therapy following decompressive surgery for CVT does not significantly influence the risk of new bleeding or venous thrombotic events or disability.


  • Virtual Reality-Induced Dissociative Symptoms: A Retrospective Study

    by Mariana C. Taveira, João de Sá, Michele Gomes da Rosa

    Objective: The use of virtual reality (VR) has been increasing worldwide, as devices are becoming more sophisticated and provide an escape from reality during the COVID-19 lockdown. This recent rise in the use of VR leads to new side effects being reported, such as dissociative symptoms that may or may not constitute a mental health concern. This retrospective study investigated the prevalence and intensity of dissociative symptoms in VR users, as well as some potential predisposing conditions that may trigger them, and their impact on the subjects' wellbeing. Materials and Methods: We conducted a survey (n = 358) that was posted on VR Facebook groups. This survey was approved by the University of Lisbon Medical Faculty's IRB, and comprised a modified version of the Clinician-Administered Dissociative State Scale (CADSS) and questions regarding potential risk factors known to induce dissociative disorders or experiences. Results: Data analysis revealed that 83.9% participants reported dissociative symptoms, with varying intensity according to CADSS ( ). Significant correlations were found between CADSS score and the time spent playing, the use of software applications (apps) that involve virtual hands or hand tracking, history of previous dissociative experiences, traumatic childhood events, avoidant coping strategies, and psychiatric disorders. Nonetheless, most participants categorized the symptoms as nonanxiogenic (85.8%) and minute lasting (77.4%). Conclusion: In conclusion, this study revealed that although VR can induce dissociative experiences, they seem to be short lasting and nonthreatening to the individual's wellbeing and might be predicted or attenuated by managing other known risk factors for dissociative phenomena.